Ventyx Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sheila K. Gujrathi
- Full Time Employees
- 81
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 662 Encinitas Boulevard San Diego CA United States of America 92024
- IPO Date
- Oct 21, 2021
- CIK
- 0001851194
- Website
- ventyxbio.com
- Similar Companies
- Business
- Ventyx Biosciences, Inc. (Nasdaq: VTYX) is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies targeting immune-mediated diseases. The company advances a pipeline of small-molecule product candidates, including VTX958, a potent allosteric TYK2 inhibitor for the treatment of moderate to severe Crohn's disease, psoriatic arthritis, and other inflammatory conditions; VTX002, a RORγt inverse agonist targeting autoimmune disorders such as psoriasis and rheumatoid arthritis; and earlier-stage candidates targeting NLRP3 inflammasome and other immune pathways. Ventyx offers research and development services in immunology and inflammation, with preclinical and clinical-stage programs aimed at addressing unmet needs in gastroenterology, dermatology, and rheumatology segments; its target markets include patients with autoimmune and inflammatory diseases served through partnerships with healthcare providers and pharmaceutical collaborators. Founded in 2018 and headquartered in San Diego, California, the company conducts operations primarily in the United States with global clinical trial sites. In recent developments within the last two years, Ventyx discontinued VTX958 following disappointing Phase 2 trial results in psoriasis in late 2023, leading to a strategic pipeline reprioritization and significant workforce reduction; the company also reported positive Phase 2 data for VTX002 in Sjögren’s disease in 2024 and advanced VTX2735, an NLRP3 inhibitor, into clinical development for neuroinflammation-related conditions.
Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm
JPMorgan Chase & Co. Has $2.33 Million Stock Holdings in Ventyx Biosciences, Inc. $VTYX
Ventyx Biosciences (NASDAQ:VTYX) Sees Strong Trading Volume – Here’s What Happened
Contrasting Ventyx Biosciences (NASDAQ:VTYX) & Clene (NASDAQ:CLNN)
Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of “Reduce” from Brokerages
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasdaq - VTYX)
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Reduce” by Analysts
Halper Sadeh LLC Encourages SEE, VTYX, SNCY Shareholders to Contact the Firm to Discuss Their Rights
Cwm LLC Cuts Stock Position in Ventyx Biosciences, Inc. $VTYX
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update
$HAREHOLDER ALERT: The M&A Class Action Reminds $hareholders of Upcoming Merger Deadlines—FFIC, OCFC, VTYX, and ONTF
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX